Cargando…
P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
Autores principales: | Vlachová, M., Štork, M., Ševčíková, S., Jelínek, T., Minařík, J., Radocha, J., Krhovská, P., Pospíšilová, L., Špička, I., Straub, J., Pavlíček, P., Jungová, A., Sandecká, V., Maisnar, V., Hájek, R., Pour, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429299/ http://dx.doi.org/10.1097/01.HS9.0000846736.70303.39 |
Ejemplares similares
-
Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021) -
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022) -
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022) -
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023) -
P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)